Electra Therapeutics prices $350m IPO

Electra Therapeutics (ETRA) began trading on Nasdaq on 18 September 2026, raising $350 million via an upsized IPO priced at $15.00 per share. HBM Healthcare Investments, which backed Electra with $30 million, now holds a 3.9% stake valued at $32.8 million. Electra's lead product, ipsoprubart, is in Phase 2/3 trials for sHLH and has received FDA and EMA designations.

Electra Therapeutics, a biotech company focused on precision immunology, raised $350M in an upsized IPO, pricing 23.3M shares at $15 each. Its lead drug, ipsoprubart, is in Phase 2/3 trials for sHLH. Shares closed at $13.25, down 12% from the IPO price. The company plans to use proceeds for clinical development and commercialization.

Electra Therapeutics priced its IPO at $15 per share, raising $350 million. The biopharmaceutical company sold 23.3 million shares, with an option for 3.5 million more. Shares will trade on Nasdaq under the ticker ETRA. The funds will support its pipeline for immune-mediated diseases and cancer.

Electra Therapeutics Inc. expects its IPO to price above the midpoint of its $14-$16 range, with strong demand from investors. The biotech company plans to offer 21.67 million shares, trading under the ticker ETRA on Nasdaq from Friday. The offering is managed by Jefferies, TD Bank, Evercore, and Cantor Fitzgerald.

Electra Therapeutics (ETRA) plans a $325 million IPO on Nasdaq, offering 21.7 million shares at $14-$16 each. Led by Jefferies, TD Cowen, Evercore ISI, and Cantor, the deal signals strong institutional interest. Pricing is expected soon, with final price indicating market demand.

Electra Therapeutics aims for a $977.6M valuation in its U.S. IPO, offering 21.67M shares at $14-$16 each, raising up to $346.7M. The biotech company develops therapies for immunological diseases and cancer, with proceeds funding clinical trials. It plans to list on Nasdaq as 'ETRA'.